Table 4. Multivariable logistic regression analysis of HSR risk factors.

	Any history of HSR			HSR on study
	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value
Age
0–55	Reference			Reference
55–70	0.93	0.31–2.8	0.89	0.5	0.13–1.9	0.32
>70	1	0.13–8.2	0.98	0.89	0.10–7.7	0.92
History of allergy
No	Reference			Reference
Yes	2.3	0.82–6.4	0.12	1.4	0.40–4.5	0.64
Platinum-free intervala
0–12 Months	NA			Reference
12–24 Months	NA			1.4	0.28–6.8	0.7
>24 Months	NA			2.6	0.49–14.1	0.26
Single maximum dosea
⩽650 mg	NA			Reference
>650 mg	NA			1	0.19–5.6	0.98
Prior carboplatin cycles
0–6	Reference			Reference
7–12	1.1	0.29–3.9	0.94	1.1	0.26–4.7	0.89
>12	2.2	0.65–7.6	0.2	1.9	0.41–8.5	0.42
BRCA mutation
No	Reference			Reference
Yes	13.1	2.6–65.4	0.0017	5.9	1.1–31.7	0.039

Abbreviations: CI=confidence interval; HSR=hypersensitivity reaction; NA=not applicable.

^aPlatinum-free interval and maximum carboplatin dose >650 mg on trial are relevant only to HSR developed on trial and were examined in the ‘HSR on study' cohort only.